nyuuzyou/wikis huggingface dataset:
Autoimmune cytopenia

Back to Top
This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.
*We have moved How I Treat articles to a dedicated page.
Last updated on 2024-07-23:2 regimens on this page
2 variants on this page
=Relapsed or refractory=
==Alemtuzumab monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence	Efficacy
Willis et al. 2001	1995-11 to 2000-08 	Phase 2 	ORR: 71%
====Immunosuppressive therapy====
*Alemtuzumab (Campath) 1 mg IV over 60 minutes once on day 1, then 10 mg IV over 4 hours once per day on days 1 to 10
10-day course
===References===
# Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Sirolimus monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence	Efficacy
Bride et al. 2015	Not reported 	Phase 2 	Durable CR observed in patients with ALPS
====Immunosuppressive therapy====
*Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
6-month course, extended for those with a favorable response
====Dose and schedule modifications====
*See manuscript for recommended dose adjustments
===References===
# Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article dosing details in abstract have been reviewed by our editors EuroPMC NCT00392951
Category:Autoimmune cytopenia regimens
Category:Disease-specific pages
Category:Autoimmune hematologic conditions
Category:Hemolytic process
Category:Cytopenias
Avatrombopag (Doptelet)

==Mechanism of action==
Thrombopoietin receptor agonist
==Diseases for which it is established==
*Immune thrombocytopenia
*Thrombocytopenia in liver disease
==History of changes in FDA indication==
* 2018-05-21: Approved for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
==History of changes in EMA indication==
*2019-06-20: Initial authorization as Doptelet
*Uncertain date: Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
*Uncertain date: Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
==Also known as==
*Code names: E-5501, YM-477, AKR-501
*Brand name: Doptelet
Category:Drugs
Category:Oral medications
Category:Hematopoietic growth factors
Category:Megakaryocyte growth factors
Category:Immune thrombocytopenia medications
Category:Thrombocytopenia in liver disease medications
Category:FDA approved in 2018
Category:EMA approved in 2019
Axatilimab (Niktimvo)

==Mechanism of action==
colony stimulating factor-1 receptor-blocking antibody
==Diseases for which it is established==
*Graft versus host disease
==History of changes in FDA indication==
*2024-08-14: Initial approval for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. (Based on AGAVE-201)
==Also known as==
*Generic name: axatilimab-csfr
*Brand name: Niktimvo
Category:Drugs
Category:Intravenous medications
Category:Anti-CSF1R antibodies
Category:Graft versus host disease medications
Category:FDA approved in 2024
Azacitidine oral (Onureg)

==General information==
Class/mechanism: Pyrimidine nucleoside analog of cytidine, causes hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation.
Route: PO
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Acute myeloid leukemia
*Myelodysplastic syndrome
== Patient Drug Information==
*Azacitidine (Onureg) Package InsertAzacitidine (Onureg) Package Insert
==History of changes in FDA indication==
* 2020-09-01: Approved for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. (Based on QUAZAR AML-001)
==History of changes in EMA indication==
*2021-06-17: Initial authorization as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT). (Based on QUAZAR AML-001)
==Also known as==
*Code name: CC-486
*Brand name: Onureg
==References==
Category:Drugs
Category:Oral medications
Category:DNA methyltransferase inhibitors
Category:Pyrimidine analogs
Category:Acute myeloid leukemia medications
Category:Myelodysplastic syndrome medications
Category:FDA approved in 2020
Category:EMA approved in 2021
B-cell acute lymphoblastic leukemia, pediatric - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main pediatric B-ALL page for regimens that include active anticancer treatment.
=Maintenance after upfront therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Yang et al. 2021 (CCCG-ALL-2015)	2015-2020 	Phase 3 (E-de-esc)	Vincristine & Dexamethasone	Non-inferior EFS60 (primary endpoint)
No active maintenance treatment beyond 1 year. Patients in this study were required to be in continuous remission for 1 year after initial treatment.
===References===
#CCCG-ALL-2015: Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, Jiang H, Fang Y, Liang C, Ju X, Wu X, Zhai X, Tian X, Wang N, Liu A, Jiang H, Jin R, Sun L, Yang M, Leung AWK, Pan K, Zhang Y, Chen J, Zhu Y, Zhang H, Li C, Yang JJ, Cheng C, Li CK, Tang J, Zhu X, Pui CH. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021 Sep;22(9):1322-1332. Epub 2021 Jul 27. link to original article link to PMC article EuroPMC ChiCTR-IPR-14005706
Category:B-cell acute lymphoblastic leukemia regimens
Category:Disease-specific pages
Category:Acute lymphoblastic leukemias
Category:Pediatric hematologic neoplasms
Category:Null regimens
B-cell lymphoma of mucosa-associated lymphoid tissue - historical

Back to Top
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? Please go to the main MALT lymphoma regimen page to find other regimens.
Last updated on 2024-07-23:TBA regimens on this page
TBA variants on this page
 
=Consolidation after first-line therapy=
==Chlorambucil monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Hancock et al. 2008 (LY03) 	1995-2001 	Phase 3 (E-esc) 	Observation	Did not meet primary endpoint of RR
Zucca et al. 2013 (IELSG-19)	2003-2005 	Non-randomized part of phase 3 RCT	 	
====Preceding treatment====
*IELSG-19: Chlorambucil induction
====Chemotherapy====
*Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 14
28-day cycle for up to 4 cycles (IELSG-19) or 6 cycles (LY03)
===References===
# LY03: Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00003617
# IELSG-19: Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00210353
## Update: Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. link to original article EuroPMC
Category:MALT lymphoma regimens
Category:Disease-specific pages
Category:Marginal zone lymphomas
Category:B-cell lymphomas
Category:Historical regimens
B-cell lymphoma of mucosa-associated lymphoid tissue - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main MALT lymphoma page for regimens that include active anticancer treatment.
=Consolidation after first-line therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Hancock et al. 2008 (LY03)	1995-2001 	Phase 3 (C)	Chlorambucil	Did not meet primary endpoint of RR
No further treatment.
====Preceding treatment====
*H. pylori eradication therapy
===References===
# LY03: Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. link to original article link to PMC article EuroPMC NCT00003617
Category:MALT lymphoma regimens
Category:Disease-specific pages
Category:Marginal zone lymphomas
Category:B-cell lymphomas
Category:Null regimens
BCG vaccine

==General information==
Class/mechanism: Live mycobacteria which promote a local acute inflammatory and sub-acute granulomatous reaction with macrophage and leukocyte infiltration in the urothelium and lamina propria of the urinary bladder. This results in a likely T-lymphocyte dependent anti-tumor effect.BCG vaccine package insert BCG vaccine package insert (locally hosted backup)
Route: Intravesicular
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Bladder cancer (intravesicular use)
==Diseases for which it was used==
*B-cell acute lymphoblastic leukemia
*Breast cancer
*Colon cancer
*Diffuse large B-cell lymphoma
*Hodgkin lymphoma
*Melanoma
*Non-small cell lung cancer
==Patient drug information==
*BCG vaccine package insert
*BCG vaccine patient drug information (Chemocare)BCG vaccine patient information (Chemocare)
*Patient information about bladder cancer treatment, including BCG (UpToDate)Patient information about bladder cancer treatment, including BCG (UpToDate)
==History of changes in FDA indication==
*1990-05-22: Initial approval for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder
*1990-05-22: Initial approval for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). (Based on SWOG 8216 & SWOG 8507)
==History of changes in EMA indication==
*1988-03-02: EURD
==History of changes in Health Canada indication==
*1994-09-08: Initial notice of compliance
==Also known as==
*Generic name: Bacille Calmette–Guérin
*Brand names: ImmuCyst, OncoTice, TheraCys, TICE BCG
==References==
Category:Drugs
Category:Intravesical medications
Category:Immunotherapeutic
Category:T-cell activators
Category:Bladder cancer medications
*Category:B-cell acute lymphoblastic leukemia medications (historic)
*Category:Breast cancer medications (historic)
*Category:Colon cancer medications (historic)
*Category:Diffuse large B-cell lymphoma medications (historic)
*Category:Classical Hodgkin lymphoma medications (historic)
*Category:Melanoma medications (historic)
*Category:Non-small cell lung cancer medications (historic)
Category:FDA approved in 1990
Category:EMA approved in 1988
Category:Health Canada approved in 1994
BE-CAR7

==Mechanism of action==
Base-edited ("off the shelf") CAR T-cells directed against CD7
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===T-cell acute lymphoblastic leukemia===
#Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, Preece R, Ottaviano G, Braybrook T, Chu J, Kubat A, Adams S, Thomas R, Gilmour K, O'Connor D, Vora A, Qasim W; Base-Edited CAR T Group. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2023 Sep 7;389(10):899-910. Epub 2023 Jun 14. link to original article EuroPMC ISRCTN15323014
Category:Anti-CD7 CAR T-cells
Category:Intravenous medications
Category:T-cell acute lymphoblastic leukemia medications (investigational)
Category:Investigational drugs
Category:Stub
BHQ-880

==General information==
Class/mechanism: Human monoclonal antibody that neutralizes Dickkopf-1 (DKK-1). DKK-1 is an antagonist of the Wnt pathway, which regulates differentiation of mesenchymal stem cells (MSC) into osteoblasts and promotes survival of active osteoblasts. Myeloma cells have been observed to overexpress DKK-1, blocking osteoblast differentiation, and promoting bone resorption. By neutralizing DKK-1, it is hypothesized that BHQ880 will promote bone formation and inhibit tumor-associated osteolytic processes.BHQ880 (Anti-DKK1 Antibody) at Novartis Oncology
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
==Patient drug information==
No information available.
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-DKK1 antibodies
Category:Investigational drugs
BL22 immunotoxin (CAT-3888)

No longer in clinical development. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.
==General information==
Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.
The original manufacturer was acquired in 2005.Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc. Development of this drug was discontinued in 2008, at which time it was superseded by the more potent and less toxic Moxetumomab pasudotox (HA22).
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Hairy cell leukemia===
# Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. link to original article EuroPMC
# Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. link to original article link to PMC article EuroPMC
==Also known as==
*Code names: CAT-3888, GCR-3888
==References==
Category:Drugs
Category:Intravenous medications
Category:Immunotoxin
Category:Anti-CD22 immunotoxins
Category:Recombinant medications
Category:Hairy cell leukemia medications (investigational)
Category:Halted drugs
Backbone

The purpose of this page is to maintain a list of commonly understood backbones - two or more drugs that form the foundation for subsequent additive regimens. In practice, therapeutic equivalents are often substituted, such as biosimilar rituximab, or prednisolone for prednisone. 
Regimen class 	Preferred regimen name 	Constituents
Chemoimmunotherapy NOS	BR 	BendamustineRituximab (Rituxan)
Chemotherapy NOS 	7+3d 	Cytarabine (Ara-C)Doxorubicin (Adriamycin)
Chemotherapy NOS 	7+3i 	Cytarabine (Ara-C)Idarubicin (Idamycin)
Chemotherapy NOS 	Capecitabine and Docetaxel (TX) 	Capecitabine (Xeloda)Docetaxel (Taxotere)
Chemotherapy NOS 	CAPIRI 	Capecitabine (Xeloda)Irinotecan (Camptosar)
Chemotherapy NOS 	CHOP 	Cyclophosphamide (Cytoxan)Doxorubicin (Adriamycin)Vincristine (Oncovin)Prednisone (Sterapred)
Platinum doublet 	Capecitabine and Cisplatin (CX) 	Capecitabine (Xeloda)Cisplatin (Platinol)
Platinum doublet 	CapeOx 	Capecitabine (Xeloda)Oxaliplatin (Eloxatin)
Platinum doublet 	Carboplatin & Docetaxel (DCb) 	Carboplatin (Paraplatin)Paclitaxel (Taxol)
Platinum doublet 	Carboplatin & Etoposide (CE) 	Carboplatin (Paraplatin)Etoposide (Vepesid)
Platinum doublet 	Carboplatin & Gemcitabine (GCb) 	Carboplatin (Paraplatin)Gemcitabine (Gemzar)
Platinum doublet 	Carboplatin & nab-Paclitaxel (CnP)	Carboplatin (Paraplatin)Paclitaxel, nanoparticle albumin-bound (Abraxane)
Platinum doublet 	Carboplatin & Paclitaxel (CP) 	Carboplatin (Paraplatin)Paclitaxel (Taxol)
Platinum doublet 	Cisplatin & Docetaxel (DC) 	Cisplatin (Platinol)Docetaxel (Taxotere)
Platinum doublet 	Cisplatin & Etoposide (EP) 	Cisplatin (Platinol)Etoposide (Vepesid)
Platinum doublet 	Cisplatin & Fluorouracil (CF) 	Cisplatin (Platinol)Fluorouracil (5-FU)
Platinum doublet 	Cisplatin & Gemcitabine (GC) 	Cisplatin (Platinol)Gemcitabine (Gemzar)
Platinum doublet 	Cisplatin & Paclitaxel (TP) 	Cisplatin (Platinol)Paclitaxel (Taxol)
Platinum doublet 	Cisplatin & Vinorelbine (CVb) 	Cisplatin (Platinol)Vinorelbine (Navelbine)
Category:General reference pages
Barasertib (AZD-1152)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable, small-molecule, dihydrogen phosphate prodrug of the pyrazoloquinazoline Aurora kinase inhibitor AZD1152–hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with potential antineoplastic activity. Upon administration and rapid conversion from the prodrug form in plasma, barasertib specifically binds to and inhibits Aurora kinase B, which results in the disruption of spindle checkpoint functions and chromosome alignment and, so, the disruption of chromosome segregation and cytokinesis. Consequently, cell division and cell proliferation are inhibited and apoptosis is induced in Aurora kinase B-overexpressing tumor cells.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Acute myeloid leukemia===
# D1531C00007: Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011 Dec 1;118(23):6030-6. Epub 2011 Oct 5. link to original article link to PMC article EuroPMC NCT00497991
# SPARK-AML1: Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A; SPARK-AML1 Investigators. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013 Jul 15;119(14):2611-9. Epub 2013 Apr 19. link to original article link to PMC article EuroPMC NCT00952588
==Also known as==
*Code name: AZD-1152
Category:Drugs
Category:Oral medications
Category:Aurora kinase inhibitors
Category:Acute myeloid leukemia medications (investigational)
Category:Investigational drugs